核苷酸切除修复系统基因表达水平与化疗药物耐药相关性的系列研究

被引：6

作者：

吴一龙

周清

机构：

[1] 广东省人民医院肿瘤中心

来源：

循证医学 | 2006年 / 01期

关键词：

肺肿瘤; RRM1; ERCC1; 药物疗法;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

<正>1 文献类型治疗。 2 证据水平 1b。 3 文献来源①Resell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in Gemcitabine/Cisplatin-treated advanced non-small cell lung cancer patients [J].Clin Cancer Res, 2004, 10(4):1318-1325. ②Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage ⅡB- ⅢA-ⅢB non-small cell lung cancer after

引用

页码：3 / 6

页数：4

共 3 条

[1]

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Rosell R,Danenberg KD,Alberola V,et al. Clinical Cancer Research . 2004

[2]

ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage Ⅳ non-smallcell lung cancer (NSCLC) patients (p). Rosell R,Cobo M,Isla D,et al. Journal of Clinical Oncology . 2005

[3]

Gene expression as a predictive marker of outcome in stage ⅡB-ⅢA-ⅢB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Rosell R,Felip E,Taron M,et al. Clin Cancer Res,2004 .

← 1 →